Humans Mitomycin Gemcitabine Hematuria *Non-Muscle Invasive Bladder Neoplasms Deoxycytidine/therapeutic use Administration Intravesical *Urinary Bladder Neoplasms/drug therapy *Cystitis Chemical cystitis Cistitis química Cáncer de vejiga sin invasión muscular Gemcitabina intravesical Intravesical gemcitabine Intravesical mitomycin Mitomicina intravesical Non-muscle invasive bladder cancer Recurrence rates Tasas de recurrencia

Humans Mitomycin/therapeutic use Antibiotics Antineoplastic BCG Vaccine/therapeutic use *Non-Muscle Invasive Bladder Neoplasms Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Administration Intravesical Neoplasm Invasiveness Bladder cancer Device-assisted Emda Intravesical drug administration Nmibc

Humans *Carcinoma Transitional Cell *Urinary Bladder Neoplasms/pathology Retrospective Studies BCG Vaccine/therapeutic use Administration Intravesical Adjuvants Immunologic *Organ Transplantation Neoplasm Invasiveness Neoplasm Recurrence Local/pathology Bcg Bladder cancer Chemotherapy Mitomycin Transplanted patients

Bacillus Calmette-Guérin Chemoablation Epirubicin Gemcitabine Intravesical therapy Mitomycin Non–muscle-invasive bladder cancer

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

Adjuvants Immunologic/administration & dosage Administration Intravesical Antibiotics Antineoplastic/administration & dosage/adverse effects Antimetabolites Antineoplastic/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bias Cause of Death Confidence Intervals Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives Disease Progression Drug Administration Schedule Humans Mitomycin/administration & dosage/adverse effects Neoplasm Recurrence Local/*drug therapy/mortality/prevention & control Randomized Controlled Trials as Topic Saline Solution/administration & dosage Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/prevention & control Gemcitabine

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage Antimetabolites Antineoplastic/*administration & dosage Deoxycytidine/administration & dosage/*analogs & derivatives Humans Mitomycin/*administration & dosage Neoplasm Invasiveness Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Gemcitabine Bladder cancer Meta-analysis Mitomycin Systematic evaluation

Administration Intravesical Antibiotics Antineoplastic/administration & dosage/*therapeutic use BCG Vaccine Carcinoma Transitional Cell/*drug therapy Humans Mitomycin/administration & dosage/*therapeutic use Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Antibiotics Antineoplastic/*therapeutic use BCG Vaccine/*therapeutic use Combined Modality Therapy Humans Mitomycin/*therapeutic use Urinary Bladder Neoplasms/*drug therapy bacillus Calmette-Guérin mitomycin C non-muscle-invasive bladder carcinoma recurrence rate meta-analysis.

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review